Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Vaccine-enhanced competition permits rational bacterial strain replacement in the gut
Swiss Fed Inst Technol, Inst Food Nutr & Hlth, Zurich, Switzerland.;Univ Oxford, MRC Weatherall Inst Mol Med WIMM, John Radcliffe Hosp, Med Res Council MRC Translat Immunol Discovery Un, Oxford, England..
Sorbonne Univ, Inst Biol Paris Seine IBPS, CNRS, Laboratoire Jean Perrin LJP, Paris, France.;Univ Libre Bruxelles ULB, Fac Sci, Unite Chronobiol Theor, Brussels, Belgium..
Univ Basel, Biozentrum, Basel, Switzerland..
Swiss Fed Inst Technol, Inst Food Nutr & Hlth, Zurich, Switzerland..
Show others and affiliations
2025 (English)In: Science, ISSN 0036-8075, E-ISSN 1095-9203, Vol. 388, no 6742, p. 74-81Article in journal (Refereed) Published
Abstract [en]

Colonization of the intestinal lumen precedes invasive infection for a wide range of enteropathogenic and opportunistic pathogenic bacteria. We show that combining oral vaccination with engineered or selected niche-competitor strains permits pathogen exclusion and strain replacement in the mouse gut lumen. This approach can be applied either prophylactically to prevent invasion of nontyphoidal Salmonella strains, or therapeutically to displace an established Escherichia coli. Both intact adaptive immunity and metabolic niche competition are necessary for efficient vaccine-enhanced competition. Our findings imply that mucosal antibodies have evolved to work in the context of gut microbial ecology by influencing the outcome of competition. This has broad implications for the elimination of pathogenic and antibiotic-resistant bacterial reservoirs and for rational microbiota engineering.

Place, publisher, year, edition, pages
American Association for the Advancement of Science (AAAS), 2025. Vol. 388, no 6742, p. 74-81
National Category
Microbiology in the Medical Area Microbiology
Identifiers
URN: urn:nbn:se:uu:diva-561493DOI: 10.1126/science.adp5011ISI: 001500692500034PubMedID: 40179176Scopus ID: 2-s2.0-105002819638OAI: oai:DiVA.org:uu-561493DiVA, id: diva2:1975766
Funder
EU, European Research Council, 865730Available from: 2025-06-24 Created: 2025-06-24 Last updated: 2025-06-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Fattinger, Stefan A.

Search in DiVA

By author/editor
Fattinger, Stefan A.Slack, Emma
By organisation
Department of Medical Biochemistry and MicrobiologyScience for Life Laboratory, SciLifeLab
In the same journal
Science
Microbiology in the Medical AreaMicrobiology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 31 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf